Lotte Group’s latest results point to a clear earnings recovery. Lotte Shopping reported second-quarter 2026 revenue of KRW 3.485 trillion and operating profit of KRW 89.9 billion. Revenue increased 4.0% from a year earlier, while operating profit surged 121.2% and net income returned to positive territory.
Lotte Chemical also maintained its return to profitability, posting second-quarter revenue of KRW 5.686 trillion and operating profit of KRW 110.1 billion. Yet viewing Lotte’s transformation solely through its quarterly earnings would overlook a more consequential development. The central shift is not simply the recovery of its established businesses, but the reallocation of capital and execution capacity from those operations into new growth industries.
At the centre of that transition is Lotte Biologics’ first manufacturing plant at the Songdo Bio Campus in Incheon. The facility has completed its main construction phase and received approval for use. Commissioning and validation are scheduled for the second half of this year, ahead of commercial production targeted for 2027.
Built with an investment of approximately KRW 1.4 trillion, the plant has a total antibody-drug manufacturing capacity of 120,000 litres, supported by eight 15,000-litre bioreactors. Lotte Biologics is also consolidating its production, quality, engineering and business development functions in Songdo. The centre of gravity is therefore moving from physical construction to the establishment of an operational manufacturing system.
Three Business Clocks Are Running Inside Lotte
Lotte is now managing three businesses that move at different speeds. Retail earnings change quarterly with consumer demand and tourist flows. Chemicals follow longer industrial cycles shaped by feedstock prices, global supply adjustments and economic conditions. Biologics requires years of investment, regulatory approval, customer audits and technology transfers before a new facility can generate meaningful revenue.
Retail operates on the fastest clock. Lotte Shopping’s second-quarter recovery was led by its department store business. Supported by higher spending from foreign visitors and strong fashion sales, department store revenue rose 9.2% year on year to KRW 891.2 billion.
Lotte Mall West Lake Hanoi in Vietnam also extended its run of record operating profit to a sixth consecutive quarter, strengthening the contribution from overseas operations. The performance suggests that Lotte’s retail strategy is moving away from expansion based on store numbers and towards improving the productivity of major locations designed as destinations where customers shop, dine and spend more time.
Foreign visitor spending and the Vietnamese market offer two complementary routes around the structural constraints of Korea’s slowing domestic demand and declining population. The risk is that greater dependence on tourism and a limited number of flagship properties could increase exposure to economic, currency and geopolitical volatility.
The chemicals clock presents a more complicated picture. Lotte Chemical’s basic chemicals division generated second-quarter revenue of KRW 3.940 trillion but only KRW 2.3 billion in operating profit. Its advanced materials division, by comparison, produced revenue of KRW 1.155 trillion and operating profit of KRW 132.5 billion.
The fact that advanced materials generated more operating profit than the company’s consolidated total reveals the continuing weakness of the commodity chemicals business. It also demonstrates why a sustained recovery cannot depend on higher production volumes alone.
The return to profit should therefore be understood not as evidence that restructuring is complete, but as an opportunity to secure more time to carry it forward. Lotte Chemical’s longer-term competitiveness will depend on how quickly it can reduce its exposure to low-margin commodity products and expand advanced materials and other businesses capable of generating more stable returns.
Biologics runs on the slowest clock. Completion of the Songdo plant is a major milestone, but CDMO competitiveness is not determined by manufacturing scale alone. The value of the facility will emerge only after it passes regulatory inspections, demonstrates consistent production quality and secures long-term contracts with global pharmaceutical companies.
Lotte Biologics is developing a dual-site strategy connecting its 40,000-litre facility in Syracuse, New York, with the 120,000-litre plant in Songdo. If Syracuse supports clinical-stage production, antibody-drug conjugates and North American customers while Songdo handles large-scale commercial manufacturing, Lotte could build an integrated platform spanning early development through commercialisation.
The use of a manufacturing control system, laboratory information management system, automated logistics and real-time monitoring is also significant. In biopharmaceutical manufacturing, digitalisation is not simply a means of reducing labour costs. It is an infrastructure for traceability and trust that connects orders, manufacturing records and quality verification while controlling deviations throughout the production process.
The Outcome Will Depend on Cash Flow and Time Management
Lotte’s portfolio restructuring is taking shape as a model in which retail and chemicals restore cash generation, low-return assets are rationalised, and long-term capital is directed towards biologics and advanced materials. This is not a simple withdrawal from established industries in favour of new ones. It is an attempt to manage businesses with different cash-generation cycles and investment payback periods within a single capital structure.
The risks are equally clear. Retail earnings remain sensitive to consumer confidence and tourism, while chemical profitability can be disrupted by oversupply and volatile feedstock prices. Biologics, meanwhile, require considerable time to secure regulatory approvals and customer orders even after construction is complete.
If cash flow from the established businesses weakens again, or if commercial contracts for the Songdo facility take longer than expected, the group’s financial burden could rise. For that reason, the most important indicators for Songdo will not be nameplate manufacturing capacity alone, but order backlog, utilisation, customer diversification and the regulatory approval timetable.
At Lotte Shopping, the question is whether growth from foreign customers and overseas properties represents a structural change rather than a temporary increase in demand. At Lotte Chemical, investors will need to assess whether advanced materials can consistently offset the weaker profitability of commodity chemicals.
Lotte’s recent recovery does not mark the completion of its transformation. Its significance lies in creating the financial room required to move into the next phase. If Lotte can coordinate the rapid cash flow of retail, the cyclical nature of chemicals and the long investment horizon of biologics, it could evolve from a group identified primarily with consumer businesses into a diversified industrial group with technology and manufacturing infrastructure.
The decisive question is therefore not which Lotte affiliate delivers the largest quarterly increase in profit. It is where the group directs the capital generated by its established businesses—and whether it can remain financially resilient until that capital becomes a durable source of competitiveness. Lotte’s next stage of growth will depend on its ability to synchronise these three business clocks.
Analysis by Korea IT Times Editorial Desk
Korean version available here:
